Headline results for the fourth quarter:
|Revenues||INR 44.3 billion ($585.6 million)||+10%|
|Profit||INR 7.6 billion ($100.6 million)||+76%|
Note: All changes are versus the prior-year period unless otherwise stated
What the company said:
GV Prasad, managing director at Dr. Reddy’s Laboratories, remarked that fiscal 2020 "has been a very positive year for the company. Progress made during the year includes [voluntary action initiated] status for [the] CTO 6 [manufacturing plant], healthy product pipeline build up, productivity improvement, and strong financial performance across our businesses."
In regards to the COVID-19 pandemic, the Indian drugmaker stated that "various initiatives have been undertaken to ensure that our manufacturing-related operations continue unabated, enabling us to serve our patients," adding that "a few products related to COVID-19 are under development." In addition, Dr. Reddy's said "we are using digital channels for enabling work from home and reaching out to doctors, customers and vendors."
To read more Top Story articles, click here.